Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available ... 2025-01-22T08:18:01Z A woman regained weight after she stopped taking semaglutide. Now she works 2 jobs to afford ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...